Drug intelligence / Profile preview

RegStem

Development stage: Phase 1
Lead developer: EMO Biomedicine
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

RegStem is an autologous mesenchymal stromal cell (MSC) therapy developed by EMO Biomedicine for the treatment of knee osteoarthritis. The product is derived from MSCs isolated from the patient's own infrapatellar fat pad, which are expanded ex vivo to reach a therapeutic concentration. Once expanded, the cells are administered via intra-articular injection into the joint cavity. The mechanism of action involves the cells' ability to promote tissue repair, regeneration, and anti-inflammatory responses, as well as their potential for chondrogenesis to restore damaged cartilage in the osteoarthritic knee.

Brand names: RegStem
Other names: autologous mesenchymal stromal cell productinfrapatellar fat pad mesenchymal stem cellsIF-MSC

Beyond the preview

Go deeper on RegStem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RegStem.

Explore the full profile